Pomanda estimates the enterprise value of QIAGEN LIMITED at £66.6m based on a Turnover of £63.9m and 1.04x industry multiple (adjusted for size and gross margin).
qiagen limitedEstimated Valuation
£41.2m
Pomanda estimates the enterprise value of QIAGEN LIMITED at £41.2m based on an EBITDA of £5.1m and a 8.04x industry multiple (adjusted for size and gross margin).
qiagen limitedEstimated Valuation
£29.5m
Pomanda estimates the enterprise value of QIAGEN LIMITED at £29.5m based on Net Assets of £12.6m and 2.35x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Qiagen LimitedOverview
Qiagen Limited is a live company located in manchester, M13 0BH with a Companies House number of 02858916. It operates in the other human health activities sector, SIC Code 86900. Founded in October 1993, it's largest shareholder is
life biotech partners b.v.
with a 100% stake. Qiagen Limited is a mature,
large sized company, Pomanda has estimated its turnover at
£63.9m with
healthy
growth in recent years.
Pomanda's financial health check has awarded Qiagen Limited a 4 rating. We use a traffic light system to show it exceeds the industry average on 5 measures and has 5 areas for improvement. Company Health Check FAQs
Health Rating4out of 5
5 Strong
1 Regular
5 Weak
Size
annual sales of £63.9m, make it larger than the average company (£798.1k)
£63.9m - Qiagen Limited
£798.1k - Industry AVG
Growth
3 year (CAGR) sales growth of 5%, show it is growing at a slower rate (6.5%)
5% - Qiagen Limited
6.5% - Industry AVG
Production
with a gross margin of 33.2%, this company has a comparable cost of product (36.5%)
33.2% - Qiagen Limited
36.5% - Industry AVG
Profitability
an operating margin of 6.7% make it more profitable than the average company (5.6%)
6.7% - Qiagen Limited
5.6% - Industry AVG
Employees
with 130 employees, this is above the industry average (19)
130 - Qiagen Limited
19 - Industry AVG
Pay Structure
on an average salary of £87.1k, the company has a higher pay structure (£27k)
£87.1k - Qiagen Limited
£27k - Industry AVG
Efficiency
resulting in sales per employee of £491.4k, this is more efficient (£51.5k)
£491.4k - Qiagen Limited
£51.5k - Industry AVG
Debtor Days
it gets paid by customers after 62 days, this is later than average (22 days)
62 days - Qiagen Limited
22 days - Industry AVG
Creditor Days
its suppliers are paid after 2 days, this is quicker than average (17 days)
2 days - Qiagen Limited
17 days - Industry AVG
Stock Days
it holds stock equivalent to 9 days, this is less than average (16 days)
9 days - Qiagen Limited
16 days - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Qiagen Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 56.5%, this is a higher level of debt than the average (27.9%)
56.5% - Qiagen Limited
27.9% - Industry AVG
QIAGEN LIMITED financials
EXPORT
Qiagen Limited's latest turnover from December 2023 is £63.9 million and the company has net assets of £12.6 million. According to their latest financial statements, Qiagen Limited has 130 employees and maintains cash reserves of 0 as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Dec 2011
Dec 2010
Dec 2009
Turnover
63,880,685
63,862,156
64,499,136
54,886,333
46,915,902
44,334,868
41,287,472
40,604,391
37,913,987
37,383,241
35,987,859
33,094,975
31,608,437
31,050,222
32,436,441
Other Income Or Grants
Cost Of Sales
42,672,624
43,726,693
46,807,743
37,981,245
30,559,938
28,108,060
26,888,383
26,707,923
24,814,936
26,455,960
25,212,729
20,215,748
19,376,580
20,164,066
18,599,290
Gross Profit
21,208,061
20,135,463
17,691,393
16,905,088
16,355,964
16,226,808
14,399,089
13,896,468
13,099,051
10,927,281
10,775,130
12,879,227
12,231,857
10,886,156
13,837,151
Admin Expenses
16,941,731
17,071,001
15,522,266
13,716,305
14,984,283
12,982,668
12,529,081
13,247,473
11,809,089
9,224,194
10,549,108
13,126,561
9,657,767
10,018,631
10,875,777
Operating Profit
4,266,330
3,064,462
2,169,127
3,188,783
1,371,681
3,244,140
1,870,008
648,995
1,289,962
1,703,087
226,022
-247,334
2,574,090
867,525
2,961,374
Interest Payable
25,249
51,017
9,610
Interest Receivable
588,490
102,388
6,535
29,138
18,635
207
94
4,214
40,184
46,075
80,895
160,894
Pre-Tax Profit
4,854,820
3,166,850
2,143,878
3,195,318
1,400,819
3,427,775
1,870,215
649,089
1,294,176
1,652,070
216,412
-207,150
2,620,165
948,420
3,122,268
Tax
-653,259
-118,143
-138,500
-719,394
-653,128
-653,591
-542,906
-4,015
-294,838
-317,338
-295,713
-77,290
-595,739
268,122
-621,567
Profit After Tax
4,201,561
3,048,707
2,005,378
2,475,924
747,691
2,774,184
1,327,309
645,074
999,338
1,334,732
-79,301
-284,440
2,024,426
1,216,542
2,500,701
Dividends Paid
14,000,000
6,250,000
Retained Profit
4,201,561
3,048,707
-11,994,622
2,475,924
747,691
2,774,184
1,327,309
645,074
999,338
1,334,732
-79,301
-284,440
-4,225,574
1,216,542
2,500,701
Employee Costs
11,323,599
10,879,563
9,607,626
8,568,173
8,006,138
6,760,273
6,742,160
6,752,513
6,842,258
5,502,658
6,368,226
6,790,847
5,353,533
4,994,714
6,130,388
Number Of Employees
130
126
119
110
105
95
90
89
90
85
96
112
109
91
89
EBITDA*
5,130,275
3,949,450
3,012,945
3,980,915
2,200,275
3,832,270
2,539,316
1,346,899
2,263,470
2,749,504
897,517
691,022
3,180,274
1,387,325
3,420,019
* Earnings Before Interest, Tax, Depreciation and Amortisation
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Dec 2011
Dec 2010
Dec 2009
Tangible Assets
1,077,269
1,630,723
1,247,073
1,375,737
1,699,362
1,436,979
1,292,912
1,551,247
962,023
1,366,956
1,251,479
1,313,940
1,383,432
1,094,880
1,223,163
Intangible Assets
16,903
35,344
53,784
72,224
90,664
5,910
127,535
145,984
164,424
Investments & Other
Debtors (Due After 1 year)
464,704
514,175
513,225
184,686
147,074
Total Fixed Assets
1,541,973
2,144,898
1,760,298
1,375,737
1,699,362
1,436,979
1,309,815
1,586,591
1,015,807
1,439,180
1,342,143
1,319,850
1,510,967
1,425,550
1,534,661
Stock & work in progress
1,156,274
987,038
985,533
854,121
2,283,962
812,402
863,463
1,124,017
1,117,582
1,155,738
2,076,084
1,548,496
2,054,723
1,709,870
1,547,643
Trade Debtors
10,935,458
10,501,043
8,761,007
8,758,121
6,734,043
7,312,781
5,077,890
4,872,167
5,811,781
5,711,882
6,265,657
5,225,892
3,775,683
4,678,523
4,456,461
Group Debtors
15,028,377
8,371,485
3,374,410
15,778,120
11,291,390
11,209,190
8,860,032
6,078,057
612,999
3,200
53,758
846,917
803,399
5,880,633
2,084,918
Misc Debtors
236,116
1,189,404
1,453,399
1,629,365
1,502,899
1,086,566
1,563,389
1,388,219
817,820
598,136
523,909
721,698
494,961
471,946
595,277
Cash
1,941,089
1,180,588
987,424
1,216,912
2,108,949
6,029,338
7,630,899
5,255,453
5,183,261
2,975,108
2,711,233
5,514,089
misc current assets
total current assets
27,356,225
21,048,970
14,574,349
28,960,816
22,992,882
21,408,363
17,581,686
15,571,409
14,389,520
15,099,855
14,174,861
13,526,264
10,103,874
15,452,205
14,198,388
total assets
28,898,198
23,193,868
16,334,647
30,336,553
24,692,244
22,845,342
18,891,501
17,158,000
15,405,327
16,539,035
15,517,004
14,846,114
11,614,841
16,877,755
15,733,049
Bank overdraft
Bank loan
Trade Creditors
269,201
596,295
107,421
87,245
55,334
40,684
208,183
163,048
240,159
192,438
589,754
160,214
237,096
315,529
359,333
Group/Directors Accounts
7,580,303
6,787,257
4,494,547
4,660,294
3,830,123
3,352,302
3,023,294
2,354,607
1,774,907
4,838,916
4,424,794
3,165,016
650,932
1,595,634
961,194
other short term finances
hp & lease commitments
other current liabilities
7,333,531
6,058,562
5,206,699
7,649,268
5,678,845
4,870,825
4,096,000
4,086,406
4,045,248
3,078,548
3,359,910
4,087,708
2,866,677
2,799,588
3,423,686
total current liabilities
15,183,035
13,442,114
9,808,667
12,396,807
9,564,302
8,263,811
7,327,477
6,604,061
6,060,314
8,109,902
8,374,458
7,412,938
3,754,705
4,710,751
4,744,213
loans
hp & lease commitments
Accruals and Deferred Income
1,144,322
1,382,474
1,205,407
624,551
288,671
489,951
246,628
563,852
other liabilities
provisions
total long term liabilities
1,144,322
1,382,474
1,205,407
624,551
288,671
489,951
246,628
563,852
total liabilities
16,327,357
14,824,588
11,014,074
13,021,358
9,852,973
8,753,762
7,574,105
7,167,913
6,060,314
8,109,902
8,374,458
7,412,938
3,754,705
4,710,751
4,744,213
net assets
12,570,841
8,369,280
5,320,573
17,315,195
14,839,271
14,091,580
11,317,396
9,990,087
9,345,013
8,429,133
7,142,546
7,433,176
7,860,136
12,167,004
10,988,836
total shareholders funds
12,570,841
8,369,280
5,320,573
17,315,195
14,839,271
14,091,580
11,317,396
9,990,087
9,345,013
8,429,133
7,142,546
7,433,176
7,860,136
12,167,004
10,988,836
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Dec 2011
Dec 2010
Dec 2009
Operating Activities
Operating Profit
4,266,330
3,064,462
2,169,127
3,188,783
1,371,681
3,244,140
1,870,008
648,995
1,289,962
1,703,087
226,022
-247,334
2,574,090
867,525
2,961,374
Depreciation
863,945
884,988
843,818
792,132
828,594
571,227
650,867
679,464
955,068
1,027,977
653,059
816,731
587,735
501,360
440,204
Amortisation
16,903
18,441
18,440
18,440
18,440
18,436
121,625
18,449
18,440
18,441
Tax
-653,259
-118,143
-138,500
-719,394
-653,128
-653,591
-542,906
-4,015
-294,838
-317,338
-295,713
-77,290
-595,739
268,122
-621,567
Stock
169,236
1,505
131,412
-1,429,841
1,471,560
-51,061
-260,554
6,435
-38,156
-920,346
527,588
-506,227
344,853
162,227
1,547,643
Debtors
6,088,548
6,474,066
-12,063,565
6,637,274
-80,205
4,107,226
3,162,868
5,095,843
929,382
-530,106
48,817
1,720,464
-6,141,745
3,932,058
7,283,730
Creditors
-327,094
488,874
20,176
31,911
14,650
-167,499
45,135
-77,111
47,721
-397,316
429,540
-76,882
-78,433
-43,804
359,333
Accruals and Deferred Income
1,036,817
1,028,930
-1,861,713
2,306,303
606,740
1,018,148
-307,630
605,010
966,700
-281,362
-727,798
1,221,031
67,089
-624,098
3,423,686
Deferred Taxes & Provisions
Cash flow from operations
-1,071,045
-1,126,460
12,965,061
392,302
777,182
-26,837
-1,168,399
-3,231,495
2,091,827
3,203,940
-272,859
543,644
8,370,083
-3,106,740
-2,249,902
Investing Activities
capital expenditure
-310,491
-1,268,638
-715,154
-468,507
-1,090,977
-715,294
-392,532
-1,268,688
-550,135
-1,143,454
-693,788
-747,239
-876,287
-373,077
-1,846,232
Change in Investments
cash flow from investments
-310,491
-1,268,638
-715,154
-468,507
-1,090,977
-715,294
-392,532
-1,268,688
-550,135
-1,143,454
-693,788
-747,239
-876,287
-373,077
-1,846,232
Financing Activities
Bank loans
Group/Directors Accounts
793,046
2,292,710
-165,747
830,171
477,821
329,008
668,687
579,700
-3,064,009
414,122
1,259,778
2,514,084
-944,702
634,440
961,194
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
share issue
-83,458
-48,145
-211,329
-142,520
-81,294
-38,374
8,488,135
interest
588,490
102,388
-25,249
6,535
29,138
18,635
207
94
4,214
-51,017
-9,610
40,184
46,075
80,895
160,894
cash flow from financing
1,381,536
2,395,098
-190,996
836,706
506,959
347,643
668,894
579,794
-3,143,253
314,960
1,038,839
2,411,748
-979,921
676,961
9,610,223
cash and cash equivalents
cash
-1,941,089
760,501
193,164
-229,488
-892,037
-3,920,389
-1,601,561
2,375,446
72,192
2,208,153
263,875
-2,802,856
5,514,089
overdraft
change in cash
-1,941,089
760,501
193,164
-229,488
-892,037
-3,920,389
-1,601,561
2,375,446
72,192
2,208,153
263,875
-2,802,856
5,514,089
qiagen limited Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for qiagen limited. Get real-time insights into qiagen limited's credit score, group structure and payment trends.
Perform a competitor analysis for qiagen limited by selecting its closest rivals, whether from the HUMAN HEALTH AND SOCIAL WORK ACTIVITIES sector, other large companies, companies in M13 area or any other competitors across 12 key performance metrics.
qiagen limited Ownership
QIAGEN LIMITED group structure
Qiagen Limited has no subsidiary companies.
Ultimate parent company
QIAGEN NV
#0026434
LIFE BIOTECH PARTNERS BV
#0156278
2 parents
QIAGEN LIMITED
02858916
QIAGEN LIMITED Shareholders
The sole shareholder of Qiagen Limited is Life Biotech Partners B.V..
life biotech partners b.v.
100%
qiagen limited directors
Qiagen Limited currently has 2 directors.
The longest serving directors include
Mr Roland Sackers (Oct 2001) and
Dr Andrew Critchley (Aug 2018).
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 1 charges/mortgages relating to qiagen limited. Currently there are 1 open charges and 0 have been satisfied in the past.
qiagen limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for QIAGEN LIMITED. This can take several minutes, an email will notify you when this has completed.
qiagen limitedCompanies House Filings - See Documents
